A team of Ropes & Gray attorneys is advising Johnson & Johnson in its acquisition of Aragon Pharmaceuticals, Inc., including rights to its second generation prostate cancer drug ARN-509, for $650 million in cash upfront and up to $350 million in contingent payments. The deal enhances Johnson & Johnson’s leadership in prostate cancer drug development, which is one of its main areas of focus, and provides the potential for novel approaches to treat prostate cancer patients.
The Ropes & Gray team included private equity transactions associates Michael Gilbert and Charlie Boer.
Articles in The Deal Pipeline and Law360 reported on this deal.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.